Loading...
The FDA-approved covalent, irreversible-binding Bruton tyrosine kinase inhibitors (BTKis) — ibrutinib, acalabrutinib, and zanubrutinib — are integral components of treatment for B-cell malignancies, but tumor cell resistance and treatment intolerance are common.
Investigators report the results of a multicenter, industry-sponsored phase 1/2 trial of a novel reversible-binding BTKi, pirtobrutinib (LOXO-305) in 323 patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL). Patients previously treated with a BTKi were included.
Among 203 patients in the phase 1 dose-findi…